The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
Launched by MICHIGAN STATE UNIVERSITY · Jan 17, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The ROSE Scale-up Study is a clinical trial aimed at finding out how effective the ROSE program is in preventing postpartum depression (PPD) among all women, not just those at higher risk. The ROSE program has already been shown to reduce PPD cases by about half in low-income women who are at increased risk. This study will involve around 2,320 women who are between 12 to 32 weeks pregnant and receiving prenatal care at Henry Ford Health in Detroit, MI. Participants will be randomly assigned to either receive the ROSE program or be part of a control group, allowing researchers to compare its effectiveness in preventing PPD and improving women's overall well-being.
To be eligible for the trial, women need to be at least 18 years old, understand English well enough to participate, and have access to a phone. However, those who are currently experiencing severe depression or have a history of bipolar or psychotic disorders cannot take part. Participants can expect to engage in questionnaires and follow-up calls during the study. This research is significant because it will help determine if providing the ROSE program universally to all pregnant women is a good strategy for preventing postpartum depression, potentially making care more accessible and cost-effective.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Is aged 18 or older
- • 2. Is receiving prenatal services within the U.S
- • 3. Is between 12-32 weeks pregnant
- • 4. Speaks and understand English well enough to understand questionnaires when they are read aloud
- • 5. Has access to a telephone through owning one, a relative/friend, or an agency
- • 6. Is willing and able to provide the name and contact information of at least two locator persons
- Exclusion Criteria:
- • 1. Has a current major depressive episode
- • 2. Has current or past diagnosis of a bipolar disorder or a psychotic disorder
About Michigan State University
Michigan State University (MSU) is a leading public research institution dedicated to advancing knowledge and improving health outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, MSU integrates cutting-edge research methodologies and expert faculty across various fields to address pressing health challenges. The university's commitment to ethical research practices and participant safety ensures that all clinical trials are conducted with the highest standards of integrity and compliance. By fostering a dynamic environment for scientific inquiry, MSU aims to translate research findings into practical solutions that enhance patient care and contribute to the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Flint, Michigan, United States
Patients applied
Trial Officials
Jennifer E Johnson, PhD
Principal Investigator
Michigan State University
Caron Zlotnick, PhD
Principal Investigator
Butler Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials